

ATLATL and Samsung Bioepis to accelerate early-stage biotech innovation across Asia-Pacific

June 25, 2026 | News

For early-stage biotech companies developing next-generation therapeutics and platform technologies



China-based ATLATL Innovation Center, a global innovation platform for life science research and development, and Korea's Samsung Bioepis have announced the launch of the Samsung Bioepis Innovation Prize C-Lab Outside (Innovation Prize), an open innovation initiative designed to identify and support promising early-stage biotech companies across the Asia-Pacific region.

The programme seeks innovative startups and emerging biotech companies working in the following therapeutic areas:

- Oncology
- Immunology & Inflammation (I&I)
- Metabolic Disease

Areas of particular interest include:

- Novel/New Mechanisms of Action (MoA)-based Antibody-Drug Conjugate (ADC)/ X-Drug Conjugates (XDC) (i.e., Payload, Linker, Conjugation)
- Antibody Engineering Technology
- New Modality (Biologics)
- Peptide (Design Engineering, Long-acting Peptide)
- Novel Target Discovery Platform

Selected companies will gain access to ATLATL's world-class laboratory infrastructure, entrepreneurial resources, and industry mentorship. In addition, awardees will have the opportunity to engage with Samsung Bioepis through its open innovation platform, enabling scientific collaboration, technology assessment, and potential future partnership opportunities.

Together, these resources are designed to accelerate innovation and support the translation of promising technologies toward commercialisation.